drugset / Trial / NCT04614636
FT538 in Subjects With Advanced Hematologic Malignancies
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a Phase I dose-finding study of FT538 as monotherapy in acute myeloid leukemia (AML) and in combination with monoclonal antibodies in multiple myeloma (MM). The study will consist of a dose-escalation stage and an expansion stage where participants will be enrolled into indication-specific cohorts.
Timeline
- Start
- 2020-10-17
- Primary completion
- 2023-07-13
- Completion
- 2023-08-08
Outcome
Outcome not reported
Stopped: “This study was terminated by the Sponsor.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Daratumumab | Monoclonal antibody | — | — |
| Subject | Elotuzumab | Monoclonal antibody | — | — |
| Subject | FT538 | Cell therapy | — | — |
| Background | Cyclophosphamide | Other / unclassified | — | — |
| Background | Fludarabine | Small molecule | — | — |